SchizophreniaPhase 2NCT01677377
Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy
A Phase 2 study testing Risperidone and RBP-7000 in people with Schizophrenia, run by Indivior Inc. at 2 sites in United States.
Trial summary
Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Schizophrenia
- What is being tested?
- Risperidone and RBP-7000
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 2 sitesUnited States
- Study dates
- Aug 2012to Apr 2013
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male and female
- > 18 to < 65 years
- Diagnosis of paranoid, residual, or undifferentiated schizophrenia as defined by Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR) criteria
- Status: clinically stable subjects defined as subjects with no hospitalizations for acute exacerbations within 3 months of screening and screening total Positive and Negative Syndrome Scale (PANSS) score < 60
- Subjects who have given written informed consent
Who cannot join
- Subjects taking any risperidone sustained release formulation within the 60 days prior to study screening
- Subjects taking the following concurrent medication/over-the-counter products:
- Inducers or inhibitors of cytochrome P450 2D6 (CYP-2D6) within 14 days or 7 half - lives (whichever occurs last) prior to study screening
- Bupropion, chlorpheniramine, cimetidine, clomipramine, doxepin, or quinidine within 30 days prior to study screening
- Clozapine, phenothiazines, aripiprazole, haloperidol, or any other antipsychotic other than oral risperidone within 14 days prior to study screening
- Selective serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine) or serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine, desvenlafaxine, duloxetine) within 30 days prior to study screening
Show all 20Show fewer
- Opioids or opioid-containing analgesics within 14 days prior to study screening
- Medications, in addition to those listed above, which may be expected to significantly interfere with the metabolism or excretion of risperidone and/or 9-hydroxyrisperidone, that may be associated with a significant drug interaction with risperidone, or that may pose a significant risk to subjects' participation in the study
- Subjects with a history of cancer (with the exception of resected basal cell or squamous cell carcinoma of the skin) unless they have been disease free for >5 years
- Subjects with another active medical condition or organ disease that may either compromise subject safety and/or outcome evaluation of the study drug
- Subjects with evidence or history of a significant hepatic disorder that may either compromise subject safety or interfere with the safety and/or outcome evaluation of the study drug. Individuals with acute hepatitis (including but not limited to B or C); or individuals with 1) total bilirubin >1.5x the upper limit of normal and/or 2) alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2x upper limit of normal (ULN) will be excluded
- Subjects with hepatitis C antibody and AST, ALT, or alkaline phosphatase >2x and total bilirubin >1.3 mg/dL will be excluded
- Subjects with a history of renal disease, or a creatinine clearance of less than 80 mL/min (as determined by the Cockcroft Gault formula)
- Subjects with an international normalized ratio >2.0 at screening
- Subjects with corrected QT interval (Bazett's - QTcB) >450 msec (male) or >470 msec (female) at screening. Subjects with a QTc above these levels due to a benign right bundle branch block can be included in the study at the discretion of the PI
- Subjects who are known to have AIDS or to be HIV positive
- Subjects with suicidal ideation with intent and plan (Columbia-Suicide Severity Rating Scale (C-SSRS) affirmative answers to questions 4 and 5 of the ideation section) or suicide attempts within the last six months as noted on the C-SSRS, or subjects with uncontrolled depression in the opinion of the investigator
- Subjects with known diagnosis of type 1 or 2 diabetes or subjects with Hemoglobin A1c >7.0 at screening
- Subjects who have participated in a clinical trial within 30 days prior to study screening
- Subjects who meet the DSM-IV-TR criteria for alcohol abuse or dependence within the last six months of screening
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Woodland International Research Group, Inc.
Little Rock, Alaska, 72211
Ocean View Psychiatric Health Facility
Long Beach, California, 90806
About this study
Official title: A Phase 2A, Open-Label, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Primary Pharmacodynamic Markers of Efficacy of 60mg, 90mg, and 120mg of Risperidone in RBP-7000 Subcutaneous Injections in Subjects With Clinically Stable Schizophrenia
Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia
Read the detailed description
This will be an open-label, Phase 2A, multiple ascending dose study in 1 to 3 sites, designed to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple subcutaneous injections of 60mg, 90mg, and 120mg doses of risperidone in the RBP-7000 formulation, in subjects with clinically-stable schizophrenia who are on a once daily stable dose of 2mg, 3mg, or 4mg of oral risperidone.
- Conditions
- Schizophrenia
- Being tested
- Risperidone, RBP-7000
- Keywords
- Schizophrenia, Schizophrenic, Schizophrenias
- Medical subject headings
- Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RisperidoneDrug
Also called Risperdal
Oral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87.
RBP-7000Drug
Also called risperidone in Atrigel
RBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57.
| Study group | Role | What they receive |
|---|---|---|
| Cohort 1, RBP-7000 60 mg | Experimental | Participants who were stable on 2 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 60 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 2 mg oral daily risperidone on days 85-87. Receives: Drug: Risperidone; Drug: RBP-7000 |
| Cohort 2, RBP-7000 90 mg | Experimental | Participants who were stable on 3 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 90 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 3 mg oral daily risperidone on days 85-87. Receives: Drug: Risperidone; Drug: RBP-7000 |
| Cohort 3, RBP-7000 120 mg | Experimental | Participants who were stable on 4 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 120 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 4 mg oral daily risperidone on days 85-87. Receives: Drug: Risperidone; Drug: RBP-7000 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Summary of Participants With Treatment-Emergent Adverse Events (TEAE)
An adverse event (AE) is defined as any study-related event that represents a change (positive or negative) in frequency or severity from a baseline (prestudy) event (if any), regardless of the presence of causal relationship or medical significance. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the first study dose date. AEs are determined by the Investigator to be related or not related to the study drug.
A serious AE (SAE) is defined by federal regulation as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Although a subject may have had 2 or more adverse experiences the subject is counted only once in a category. The same subject may appear in different categories.
Measured: Day 1 to Day 106
Total Risperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24)
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
AUC0-24 calculated using the linear trapezoidal rule.
Results are reported across two timeframes:
- Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection)
- Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-2, Day 57-58
Total Risperidone PK: Maximum Plasma Concentration (Cmax) During Initial Peak
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
Cmax determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection)
- Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-2, Day 57-58
Total Risperidone PK: Time of Maximum Plasma Concentration (Tmax) During Initial Peak
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
Tmax determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection)
- Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-2, Day 57-58
Total Risperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to Time Tau (Where Tau=28 Days) (AUCtau)
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
AUCtau calculated using the linear trapezoidal rule.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Total Risperidone PK: Average Plasma Concentration (Cavg) Over the PK Profile
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
The average of plasma concentrations calculated as AUCtau/ tau (tau = 28 days)
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Total Risperidone PK: Maximum Plasma Concentration (Cmax) Over the PK Profile
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
Maximum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Total Risperidone PK: Minimum Plasma Concentration (Cmin) Over the PK Profile
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
Minimum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Total Risperidone PK: Percent Fluctuation Over the PK Profile
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Total Risperidone PK: Swing Over the PK Profile
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Total Risperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the PK Profile
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Total Risperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Area Under the Plasma Concentration Curve (Rac(AUC))
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
Accumulation index in terms of AUC calculated as ratio of AUCtau injection 3 / injection 1. Tau = 28 days.
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Total Risperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Maximum Plasma Concentrations (Rac(Cmax))
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
Accumulation index in terms of Cmax calculated as ratio of Cmax injection 3 / injection 1.
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Total Risperidone PK: Area Under the Plasma Concentration-Time Curve From Day 2-29 Post Injection (AUC Day 2-29)
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
Area under plasma concentration-time curve from 24 hours (Day 2) to the last quantifiable collection during dosing interval (28 days); calculated using the linear trapezoidal rule.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 at time of study drug administration.
Measured: Day 2-29, Day 58-85
Total Risperidone PK: Average Plasma Concentration Over the Secondary Peak (Cavg, Day 2-29)
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
The average of plasma concentrations in the plateau, calculated as AUC Day 2-29/time
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Total Risperidone PK: Maximum Plasma Concentration Over the Secondary Peak (Cmax)
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
Maximum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
Secondary Peak, Injection 1 (Day 2 - Day 29) Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Total Risperidone PK: Minimum Plasma Concentration (Cmin) Over the Secondary Peak
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
Minimum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Total Risperidone PK: Percent Fluctuation Over the Secondary Peak
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Total Risperidone PK: Swing Over the Secondary Peak
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Total Risperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the Secondary Peak
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone:
- [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone]
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Risperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24)
AUC0-24 calculated using the linear trapezoidal rule.
Results are reported across two timeframes:
- Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection)
- Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-2, Day 57-58
Risperidone PK: Maximum Plasma Concentration (Cmax) During Initial Peak
Cmax determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection)
- Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-2, Day 57-58
Risperidone PK: Time of Maximum Plasma Concentration (Tmax) During Initial Peak
Tmax determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection)
- Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-2, Day 57-58
Risperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to Time Tau (Where Tau=28 Days) (AUCtau)
AUCtau calculated using the linear trapezoidal rule.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Risperidone PK: Average Plasma Concentration (Cavg) Over the PK Profile
The average of plasma concentrations calculated as AUCtau/ tau (tau = 28 days)
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Risperidone PK: Maximum Plasma Concentration (Cmax) Over the PK Profile
Maximum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Risperidone PK: Minimum Plasma Concentration (Cmin) Over the PK Profile
Minimum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Risperidone PK: Percent Fluctuation Over the PK Profile
The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Risperidone PK: Swing Over the PK Profile
The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Risperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the PK Profile
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Risperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Area Under the Plasma Concentration Curve (Rac(AUC))
Accumulation index in terms of AUC calculated as ratio of AUCtau injection 3 / injection 1. Tau = 28 days.
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Risperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Maximum Plasma Concentrations (Rac(Cmax))
Accumulation index in terms of Cmax calculated as ratio of Cmax injection 3 / injection 1.
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
Risperidone PK: Area Under the Plasma Concentration-Time Curve From Day 2-29 Post Injection (AUC Day 2-29)
Area under plasma concentration-time curve from 24 hours (Day 2) to the last quantifiable collection during dosing interval (28 days); calculated using the linear trapezoidal rule.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Risperidone PK: Average Plasma Concentration Over the Secondary Peak (Cavg, Day 2-29)
The average of plasma concentrations in the plateau, calculated as AUC Day 2-29/time
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Risperidone PK: Maximum Plasma Concentration Over the Secondary Peak (Cmax)
Maximum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
Secondary Peak, Injection 1 (Day 2 - Day 29) Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Risperidone PK: Minimum Plasma Concentration (Cmin) Over the Secondary Peak
Minimum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Risperidone PK: Percent Fluctuation Over the Secondary Peak
The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Risperidone PK: Swing Over the Secondary Peak
The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Risperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the Secondary Peak
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
9-hydroxyrisperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24)
AUC0-24 calculated using the linear trapezoidal rule.
Results are reported across two timeframes:
- Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection)
- Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-2, Day 57-58
9-hydroxyrisperidone PK: Maximum Plasma Concentration (Cmax) During Initial Peak
Cmax determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection)
- Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-2, Day 57-58
9-hydroxyrisperidone PK: Time of Maximum Plasma Concentration (Tmax) During Initial Peak
Tmax determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection)
- Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-2, Day 57-58
9-hydroxyrisperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to Time Tau (Where Tau=28 Days) (AUCtau)
AUCtau calculated using the linear trapezoidal rule.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
9-hydroxyrisperidone PK: Average Plasma Concentration (Cavg) Over the PK Profile
The average of plasma concentrations calculated as AUCtau/ tau (tau = 28 days)
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
9-hydroxyrisperidone PK: Maximum Plasma Concentration (Cmax) Over the PK Profile
Maximum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
9-hydroxyrisperidone PK: Minimum Plasma Concentration (Cmin) Over the PK Profile
Minimum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
9-hydroxyrisperidone PK: Percent Fluctuation Over the PK Profile
The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
9-hydroxyrisperidone PK: Swing Over the PK Profile
The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin.
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
9-hydroxyrisperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the PK Profile
Results are reported across two timeframes:
- Overall, Injection 1 (Day 1 injection to Day 28)
- Overall, Injection 3 (Day 57 injection to Day 84)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
9-hydroxyrisperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Area Under the Plasma Concentration Curve (Rac(AUC))
Accumulation index in terms of AUC calculated as ratio of AUCtau injection 3 / injection 1. Tau = 28 days.
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
9-hydroxyrisperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Maximum Plasma Concentrations (Rac(Cmax))
Accumulation index in terms of Cmax calculated as ratio of Cmax injection 3 / injection 1.
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 1-28, Day 57-84
9-hydroxyrisperidone PK: Area Under the Plasma Concentration-Time Curve From Day 2-29 Post Injection (AUC Day 2-29)
Area under plasma concentration-time curve from 24 hours (Day 2) to the last quantifiable collection during dosing interval (28 days); calculated using the linear trapezoidal rule.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
9-hydroxyrisperidone PK: Average Plasma Concentration Over the Secondary Peak (Cavg, Day 2-29)
The average of plasma concentrations in the plateau, calculated as AUC Day 2-29/time
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
9-hydroxyrisperidone PK: Maximum Plasma Concentration Over the Secondary Peak (Cmax)
Maximum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
Secondary Peak, Injection 1 (Day 2 - Day 29) Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
9-hydroxyrisperidone PK: Minimum Plasma Concentration (Cmin) Over the Secondary Peak
Minimum plasma concentrations determined directly from individual concentration-time data.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
9-hydroxyrisperidone PK: Percent Fluctuation Over the Secondary Peak
The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
9-hydroxyrisperidone PK: Swing Over the Secondary Peak
The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin.
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
9-hydroxyrisperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the Secondary Peak
Results are reported across two timeframes:
- Secondary Peak, Injection 1 (Day 2 - Day 29)
- Secondary Peak, Injection 3 (Day 58 - Day 85)
The PK sampling schedule was:
- Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose
- Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Measured: Day 2-29, Day 58-85
Secondary outcomes (6)
Positive and Negative Syndrome Scale (PANSS) Scores at Baseline and Days 28, 56, 84 and 106
The switch from oral risperidone to RBP-7000 subcutaneous injections for efficacy markers used the PANSS scores. The PANSS assessment is a medical scale designed to measure symptom severity among patients with schizophrenia. Each item is rated on a scale of 1=absent to 7=extreme. PANSS consists of three components:
- The General Psychopathology Scale consists of 16 questions with a total range of 16 (no schizophrenia symptoms) to 112 (extreme schizophrenia symptoms).
- Both the Positive Scale and the Negative Scale consists of 7 questions with a total range of 7 (no schizophrenia symptoms) to 49 (extreme symptoms) on each scale.
The PANSS range for assuring stability was a total PANSS General Psychopathology Scale score of 70 or less, with no score of 4 on any of the 7 questions in the Positive scale.
Measured: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Clinical Global Impression (CGI) Scores (Severity of Illness and Global Improvement) at Baseline and Days 28, 56, 84 and 106
The switch from oral risperidone to RBP-7000 subcutaneous injections for efficacy markers used CGI scores. The CGI is used in the assessment of global illness severity and change in clinical condition over time in psychiatric patients.
Severity of illness is measured on a 7-point scale with 1=normal, not at all ill and 7=among the most extremely ill patients.
Global improvement is measured on a 7-point scale with 1=very much improved, 4=no change and 7=very much worse as compared to the severity of illness at baseline.
Measured: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Global Assessment of the Abnormal Involuntary Movement Scale (AIMS) for Tardive Dyskinesia at Baseline and Days 28, 56, 84 and 106
The switch from oral risperidone to RBP-7000 subcutaneous injections for safety markers used AIMS. The AIMS is a scale that aids in the early detection and ongoing monitoring of tardive dyskinesia, a movement disorder that can result from long-term treatment with antipsychotic medication. By assessing the participant's body movement in specific positions requiring rotation, a psychiatrist is able to determine whether abnormal facial or body movements exist.
The total score is the sum of 7 questions assessing movement plus 3 questions representing global assessments on the overall level of involuntary movement severity, incapacitation due to involuntary movement, and patient's awareness of involuntary movement. Each of the 10 questions are scored on a 0 (none) - 4 (extremely severe) scale. Plus two dental status questions are scored on a 0 (no) - 1 (yes) scale. The total score is therefore a scale of 0 (normal) - 42 (advanced tardive dyskinesia).
Measured: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Total Simpson-Angus Scale (SAS) Score at Baseline and Days 28, 56, 84 and 106
The switch from oral risperidone to RBP-7000 subcutaneous injections for safety markers used SAS. The SAS is a 10-item scale used to detect the presence of drug induced parkinsonism and extrapyramidal side effects, and evaluates symptom severity. The ten items focus on rigidity rather than bradykinesia, and do not assess subjective rigidity or slowness. Items are rated for severity on a 0 to 4 scale with 0=normal and 4=extreme description of the particular side effect. The total range is 0=no side effects observed to 40 = extreme of each of the 10 side effects.
Measured: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Global Clinical Assessment of Akathisia Using the Barnes Akathisia Scale (BAS) at Baseline and Days 28, 56, 84 and 106
The BAS is a scale that detects the presence and severity of any drug induced akathisia. The scale measures objective and subjective effects such as restlessness and awareness of restlessness, respectively. Participants are observed while seated, then while standing and engaged in neutral conversation. Symptoms observed during additional situations, such as participant behavior on the ward, may also be rated. Subjective phenomena should be elicited through direct questioning of the participant. The global clinical assessment is reported on a scale of 0 to 5, where 0 = absent and 5 = severe akathisia.
Measured: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Participants With Suicidal Ideation or Behavior as Identified Using the Columbia-Suicide Severity Rating Scale (C-SSRS) Score at Baseline and Days 28, 56, 84 and 106
The C-SSRS is a scale developed by the National Institute of Mental Health trial group as a counterpart to the FDA's categorization of suicidal events. It was developed by a careful review and consequent categorization of thoughts and behavior that were statistically identified as significantly related to suicidal behavior. The scale captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors throughout lifetime at screening, baseline, and for the time interval since last administration for repeat administrations during a study.
This outcome reports the number of participants with suicidal ideation or behavior.
Measured: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2012 (estimated)
- Study startAug 2012
- Primary completionApr 2013
- Study completionApr 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- Indivior Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Philippa Whitelaw, Sr. Dir of Proj Deliver, Study director, Pharmaceutical Research AssociatesAshley Huston, PMP, Study director, Pharmaceutical Research Associates
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01677377
- Sponsor's protocol ID
- RB-US-09-0009
- Status last verified
- Oct 2018
- First submitted
- 27 Aug 2012
- Last updated
- 23 Oct 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2A, Open-Label, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Primary Pharmacodynamic Markers of Efficacy of 60mg, 90mg, and 120mg of Risperidone in RBP-7000 Subcutaneous Injections in Subjects With Clinically Stable Schizophrenia
- ClinicalTrials.gov ID
- NCT01677377
- Acronym / sponsor ID
- RB-US-09-0009
- Conditions
- Schizophrenia
- Keywords
- Schizophrenia, Schizophrenic, Schizophrenias
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 45 participants (actual)
- Lead sponsor
- Indivior Inc.Industry (pharma, biotech, devices)
- Study start
- Aug 2012
- Primary completion
- Apr 2013 (actual)
- Study completion
- Apr 2013 (actual)
- First posted
- 3 Sep 2012 (estimated)
- Results
- Posted 23 Oct 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluate the safety and tolerability of multiple subcutaneous injections of various dosages of risperidone with clinically stable schizophrenia
Detailed description
This will be an open-label, Phase 2A, multiple ascending dose study in 1 to 3 sites, designed to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple subcutaneous injections of 60mg, 90mg, and 120mg doses of risperidone in the RBP-7000 formulation, in subjects with clinically-stable schizophrenia who are on a once daily stable dose of 2mg, 3mg, or 4mg of oral risperidone.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Cohort 1, RBP-7000 60 mg | Experimental | Drug: Risperidone, Drug: RBP-7000Participants who were stable on 2 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 60 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 2 mg oral daily risperidone on days 85-87. |
| Cohort 2, RBP-7000 90 mg | Experimental | Drug: Risperidone, Drug: RBP-7000Participants who were stable on 3 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 90 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 3 mg oral daily risperidone on days 85-87. |
| Cohort 3, RBP-7000 120 mg | Experimental | Drug: Risperidone, Drug: RBP-7000Participants who were stable on 4 mg oral daily risperidone during the run-in period received 3 single,unblinded, subcutaneous (SC) injection doses of 120 mg risperidone in RBP-7000 on study days 1, 29 and 57. Participants returned to 4 mg oral daily risperidone on days 85-87. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male and female
- > 18 to < 65 years
- Diagnosis of paranoid, residual, or undifferentiated schizophrenia as defined by Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revision (DSM-IV-TR) criteria
- Subjects who have given written informed consent
Key exclusion criteria (20 listed)
- Subjects taking any risperidone sustained release formulation within the 60 days prior to study screening
- Subjects taking the following concurrent medication/over-the-counter products:
- Inducers or inhibitors of cytochrome P450 2D6 (CYP-2D6) within 14 days or 7 half - lives (whichever occurs last) prior to study screening
- Bupropion, chlorpheniramine, cimetidine, clomipramine, doxepin, or quinidine within 30 days prior to study screening
- Clozapine, phenothiazines, aripiprazole, haloperidol, or any other antipsychotic other than oral risperidone within 14 days prior to study screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RisperidoneAlso: RisperdalOral risperidone was supplied as 2, 3, or 4 mg tablets in blister packs or bottles and taken daily only during the oral dosing periods of the study, days -14 through -8 (if applicable), days -7 through -1, and days 85 through 87. | Drug | Cohort 1, RBP-7000 60 mg, Cohort 2, RBP-7000 90 mg, Cohort 3, RBP-7000 120 mg |
| RBP-7000Also: risperidone in AtrigelRBP-7000 60 mg, 90 mg, and 120 mg were a mixture of the ATRIGEL® Delivery System and 60 mg, 90 mg, or 120 mg risperidone, respectively. Treatment was delivered as subcutaneous injections on study days 1, 29 and 57. | Drug | Cohort 1, RBP-7000 60 mg, Cohort 2, RBP-7000 90 mg, Cohort 3, RBP-7000 120 mg |
Primary outcome
Summary of Participants With Treatment-Emergent Adverse Events (TEAE)
Time frame: Day 1 to Day 106
An adverse event (AE) is defined as any study-related event that represents a change (positive or negative) in frequency or severity from a baseline (prestudy) event (if any), regardless of the presence of causal relationship or medical significance. Treatment-emergent adverse events are defined as any adverse event with a start date on or after the first study dose date. AEs are determined by the Investigator to be related or not related to the study drug. A serious AE (SAE) is defined by federal regulation as any AE occurring at any dose that results in any of the following outcomes: death, life-threatening AE, hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect. Although a subject may have had 2 or more adverse experiences the subject is counted only once in a category. The same subject may appear in different categories.
Total Risperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24)
Time frame: Day 1-2, Day 57-58
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] AUC0-24 calculated using the linear trapezoidal rule. Results are reported across two timeframes: * Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection) * Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Maximum Plasma Concentration (Cmax) During Initial Peak
Time frame: Day 1-2, Day 57-58
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] Cmax determined directly from individual concentration-time data. Results are reported across two timeframes: * Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection) * Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Time of Maximum Plasma Concentration (Tmax) During Initial Peak
Time frame: Day 1-2, Day 57-58
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] Tmax determined directly from individual concentration-time data. Results are reported across two timeframes: * Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection) * Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to Time Tau (Where Tau=28 Days) (AUCtau)
Time frame: Day 1-28, Day 57-84
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] AUCtau calculated using the linear trapezoidal rule. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Average Plasma Concentration (Cavg) Over the PK Profile
Time frame: Day 1-28, Day 57-84
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] The average of plasma concentrations calculated as AUCtau/ tau (tau = 28 days) Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Maximum Plasma Concentration (Cmax) Over the PK Profile
Time frame: Day 1-28, Day 57-84
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] Maximum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Minimum Plasma Concentration (Cmin) Over the PK Profile
Time frame: Day 1-28, Day 57-84
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] Minimum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Percent Fluctuation Over the PK Profile
Time frame: Day 1-28, Day 57-84
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Swing Over the PK Profile
Time frame: Day 1-28, Day 57-84
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the PK Profile
Time frame: Day 1-28, Day 57-84
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Area Under the Plasma Concentration Curve (Rac(AUC))
Time frame: Day 1-28, Day 57-84
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] Accumulation index in terms of AUC calculated as ratio of AUCtau injection 3 / injection 1. Tau = 28 days. The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Maximum Plasma Concentrations (Rac(Cmax))
Time frame: Day 1-28, Day 57-84
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] Accumulation index in terms of Cmax calculated as ratio of Cmax injection 3 / injection 1. The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Area Under the Plasma Concentration-Time Curve From Day 2-29 Post Injection (AUC Day 2-29)
Time frame: Day 2-29, Day 58-85
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] Area under plasma concentration-time curve from 24 hours (Day 2) to the last quantifiable collection during dosing interval (28 days); calculated using the linear trapezoidal rule. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 at time of study drug administration.
Total Risperidone PK: Average Plasma Concentration Over the Secondary Peak (Cavg, Day 2-29)
Time frame: Day 2-29, Day 58-85
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] The average of plasma concentrations in the plateau, calculated as AUC Day 2-29/time Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Maximum Plasma Concentration Over the Secondary Peak (Cmax)
Time frame: Day 2-29, Day 58-85
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] Maximum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: Secondary Peak, Injection 1 (Day 2 - Day 29) Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Minimum Plasma Concentration (Cmin) Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] Minimum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Percent Fluctuation Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Swing Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Total Risperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
Total risperidone concentration (risperidone and 9-hydroxyrisperidone) was determined by adding risperidone concentration to risperidone-equivalent concentration (obtained from the 9-hydroxyrisperidone data). Total risperidone concentration was calculated using the molecular weights of 410 for risperidone and 426 for 9-hydroxyrisperidone: * [Total Risperidone] = [Risperidone] + (410/426) * [9-hydroxyrisperidone] Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24)
Time frame: Day 1-2, Day 57-58
AUC0-24 calculated using the linear trapezoidal rule. Results are reported across two timeframes: * Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection) * Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Maximum Plasma Concentration (Cmax) During Initial Peak
Time frame: Day 1-2, Day 57-58
Cmax determined directly from individual concentration-time data. Results are reported across two timeframes: * Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection) * Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Time of Maximum Plasma Concentration (Tmax) During Initial Peak
Time frame: Day 1-2, Day 57-58
Tmax determined directly from individual concentration-time data. Results are reported across two timeframes: * Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection) * Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to Time Tau (Where Tau=28 Days) (AUCtau)
Time frame: Day 1-28, Day 57-84
AUCtau calculated using the linear trapezoidal rule. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Average Plasma Concentration (Cavg) Over the PK Profile
Time frame: Day 1-28, Day 57-84
The average of plasma concentrations calculated as AUCtau/ tau (tau = 28 days) Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Maximum Plasma Concentration (Cmax) Over the PK Profile
Time frame: Day 1-28, Day 57-84
Maximum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Minimum Plasma Concentration (Cmin) Over the PK Profile
Time frame: Day 1-28, Day 57-84
Minimum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Percent Fluctuation Over the PK Profile
Time frame: Day 1-28, Day 57-84
The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Swing Over the PK Profile
Time frame: Day 1-28, Day 57-84
The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the PK Profile
Time frame: Day 1-28, Day 57-84
Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Area Under the Plasma Concentration Curve (Rac(AUC))
Time frame: Day 1-28, Day 57-84
Accumulation index in terms of AUC calculated as ratio of AUCtau injection 3 / injection 1. Tau = 28 days. The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Maximum Plasma Concentrations (Rac(Cmax))
Time frame: Day 1-28, Day 57-84
Accumulation index in terms of Cmax calculated as ratio of Cmax injection 3 / injection 1. The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Area Under the Plasma Concentration-Time Curve From Day 2-29 Post Injection (AUC Day 2-29)
Time frame: Day 2-29, Day 58-85
Area under plasma concentration-time curve from 24 hours (Day 2) to the last quantifiable collection during dosing interval (28 days); calculated using the linear trapezoidal rule. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Average Plasma Concentration Over the Secondary Peak (Cavg, Day 2-29)
Time frame: Day 2-29, Day 58-85
The average of plasma concentrations in the plateau, calculated as AUC Day 2-29/time Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Maximum Plasma Concentration Over the Secondary Peak (Cmax)
Time frame: Day 2-29, Day 58-85
Maximum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: Secondary Peak, Injection 1 (Day 2 - Day 29) Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Minimum Plasma Concentration (Cmin) Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
Minimum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Percent Fluctuation Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Swing Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
Risperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24)
Time frame: Day 1-2, Day 57-58
AUC0-24 calculated using the linear trapezoidal rule. Results are reported across two timeframes: * Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection) * Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Maximum Plasma Concentration (Cmax) During Initial Peak
Time frame: Day 1-2, Day 57-58
Cmax determined directly from individual concentration-time data. Results are reported across two timeframes: * Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection) * Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Time of Maximum Plasma Concentration (Tmax) During Initial Peak
Time frame: Day 1-2, Day 57-58
Tmax determined directly from individual concentration-time data. Results are reported across two timeframes: * Initial Peak, Injection 1 (Day 1 injection to 24 hours after injection) * Initial Peak, Injection 3 (Day 57 injection to 24 hours after injection) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Area Under the Plasma Concentration-Time Curve From Time Zero to Time Tau (Where Tau=28 Days) (AUCtau)
Time frame: Day 1-28, Day 57-84
AUCtau calculated using the linear trapezoidal rule. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Average Plasma Concentration (Cavg) Over the PK Profile
Time frame: Day 1-28, Day 57-84
The average of plasma concentrations calculated as AUCtau/ tau (tau = 28 days) Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Maximum Plasma Concentration (Cmax) Over the PK Profile
Time frame: Day 1-28, Day 57-84
Maximum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Minimum Plasma Concentration (Cmin) Over the PK Profile
Time frame: Day 1-28, Day 57-84
Minimum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Percent Fluctuation Over the PK Profile
Time frame: Day 1-28, Day 57-84
The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Swing Over the PK Profile
Time frame: Day 1-28, Day 57-84
The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin. Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the PK Profile
Time frame: Day 1-28, Day 57-84
Results are reported across two timeframes: * Overall, Injection 1 (Day 1 injection to Day 28) * Overall, Injection 3 (Day 57 injection to Day 84) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Area Under the Plasma Concentration Curve (Rac(AUC))
Time frame: Day 1-28, Day 57-84
Accumulation index in terms of AUC calculated as ratio of AUCtau injection 3 / injection 1. Tau = 28 days. The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Accumulation Index Between Injections 1 and 3 In Terms of Maximum Plasma Concentrations (Rac(Cmax))
Time frame: Day 1-28, Day 57-84
Accumulation index in terms of Cmax calculated as ratio of Cmax injection 3 / injection 1. The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Area Under the Plasma Concentration-Time Curve From Day 2-29 Post Injection (AUC Day 2-29)
Time frame: Day 2-29, Day 58-85
Area under plasma concentration-time curve from 24 hours (Day 2) to the last quantifiable collection during dosing interval (28 days); calculated using the linear trapezoidal rule. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Average Plasma Concentration Over the Secondary Peak (Cavg, Day 2-29)
Time frame: Day 2-29, Day 58-85
The average of plasma concentrations in the plateau, calculated as AUC Day 2-29/time Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Maximum Plasma Concentration Over the Secondary Peak (Cmax)
Time frame: Day 2-29, Day 58-85
Maximum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: Secondary Peak, Injection 1 (Day 2 - Day 29) Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Minimum Plasma Concentration (Cmin) Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
Minimum plasma concentrations determined directly from individual concentration-time data. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Percent Fluctuation Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
The degree of fluctuation of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cavg, expressed as a percentage. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Swing Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
The swing of total risperidone plasma concentrations calculated as (Cmax - Cmin) / Cmin. Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
9-hydroxyrisperidone PK: Time of the Maximum Plasma Concentration (Tmax) Over the Secondary Peak
Time frame: Day 2-29, Day 58-85
Results are reported across two timeframes: * Secondary Peak, Injection 1 (Day 2 - Day 29) * Secondary Peak, Injection 3 (Day 58 - Day 85) The PK sampling schedule was: * Days 1 and 57: within 15 minutes prior to dosing, and at 1, 2, 3, 4, 6, and 12 hours post-dose * Days 2, 4, 6, 8-12, 15, 18, 22, 25, 58, 60, 62, 64-68, 71, 74, 78, 81 once each day at same time of day as study drug administration
6 secondary outcomes
Positive and Negative Syndrome Scale (PANSS) Scores at Baseline and Days 28, 56, 84 and 106
Time frame: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Clinical Global Impression (CGI) Scores (Severity of Illness and Global Improvement) at Baseline and Days 28, 56, 84 and 106
Time frame: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Global Assessment of the Abnormal Involuntary Movement Scale (AIMS) for Tardive Dyskinesia at Baseline and Days 28, 56, 84 and 106
Time frame: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Total Simpson-Angus Scale (SAS) Score at Baseline and Days 28, 56, 84 and 106
Time frame: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Global Clinical Assessment of Akathisia Using the Barnes Akathisia Scale (BAS) at Baseline and Days 28, 56, 84 and 106
Time frame: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Participants With Suicidal Ideation or Behavior as Identified Using the Columbia-Suicide Severity Rating Scale (C-SSRS) Score at Baseline and Days 28, 56, 84 and 106
Time frame: Baseline (Day -1), Days 28, 56, 84, and End of Study (Day 106 or early termination visit)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
Treatment Resistant Disorders
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Philippa Whitelaw, Sr. Dir of Proj Deliver study director
Pharmaceutical Research Associates
Ashley Huston, PMP study director
Pharmaceutical Research Associates
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Risperidone and RBP-7000 in people with Schizophrenia, run by Indivior Inc. at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Oct 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Summary of Participants With Treatment-Emergent Adverse Events (TEAE) (time frame: Day 1 to Day 106). The study lists 58 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2018.